Multiple Myeloma Coverage From Every Angle
Editor:
Shaji K. Kumar, MD
Advertisement
Advertisement

Recent News

Potential of bb2121 CAR T-Cell Therapy in Resistant Multiple Myeloma
UAB Leads Recruitment for Novel Clinical Trial in Multiple Myeloma
Phase III ADMYRE Trial: Plitidepsin + Dexamethasone in Resistant Myeloma
FDA Issues Warning About Long-Term Use of Azithromycin After Donor Stem Cell Transplant
Pembrolizumab in Combination Therapy for Resistant Multiple Myeloma
FDA Grants Orphan Drug Designation to Human Antibody for Treatment of Multiple Myeloma
FDA Grants Fast Track Designation to Galinpepimut-S for Treatment of Myeloma
Preliminary Safety Results of Triplet Therapy for Multiple Myeloma Reported
Stand Up To Cancer Launches Dream Team to Detect Precursor Conditions of Myeloma
Clinical Trials Testing Daratumumab With Checkpoint Inhibitors in Multiple Myeloma Halted
EHA 2018: Addition of Elotuzumab to Pomalidomide and Dexamethasone in Resistant Myeloma
FDA Takes Closer Look at Use of Pembrolizumab in Multiple Myeloma
EHA 2018: Selinexor and Bortezomib Combination in Resistant Multiple Myeloma
EHA 2018: First-in-Class Selinexor in Combination Therapy for Resistant Multiple Myeloma
ASCO 2018: Novel Drug Combination Active in Relapsed Myeloma
ASCO 2018: New Phase III Data on Ibrutinib Plus Rituximab for Waldenström’s Macroglobulinemia
ASCO 2018: Halted Study Reveals Risks of Pembrolizumab Treatment in Multiple Myeloma
ASCO 2018: Once-Weekly Carfilzomib Dosing in Relapsed/Refractory Multiple Myeloma
ASCO 2018: OPTIMISMM Trial Results of Pomalidomide Triplet in Resistant Myeloma
Cancer Vaccine Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma
Novel Chip-Based Blood Assay for Isolation of Circulating Plasma Cells in Myeloma
Clinical Trial to Investigate Benefit of Exercise Prior to Stem Cell Transplantation in Myeloma
Multiple Myeloma Precursor Disease in World Trade Center Firefighters
FDA Approves Daratumumab in Combination With VMP for Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Foundation Awards $7M to Advance Immunotherapy Research
Comparing Donor Lymphocyte Infusions for Myeloid Malignancies
Melphalan Conditioning Regimens Compared in Patients With Multiple Myeloma
FDA Lifts Clinical Hold on Studies of BPX-501
FDA Grants Fast Track Designation to Selinexor for Refractory Multiple Myeloma
EBMT 2018: Induction Therapy Prior to Surgery in Patients With Multiple Myeloma
How Common Is Cognitive Impairment Among Older Patients With Blood Cancers?
Private Foundation Funds Translational Research in Multiple Myeloma
Drug Combination Tested in Those With Resistant Myeloma and Renal Impairment
CAR T-Cell Therapy Clinical Trial Enrolling Patients With Myeloma
Amifostine in Reducing GI Toxicity in Myeloma Patients After Marrow Transplant
Copyright © 2018 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.